Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Loss of Wasl improves pancreatic cancer outcome
Ana Hidalgo-Sastre, Judit Desztics, Zahra Dantes, Katharina Schulte, Hilal Kabadayi Ensarioglu, Blessing Bassey-Archibong, Rupert Öllinger, Thomas Engleiter, Lyndsay Rayner, Henrik Einwächter, Juliet M. Daniel, Ali Sameer Abdulghani Altaee, Katia Steiger, Marina Lesina, Roland Rad, Maximilian Reichert, Guido von Figura, Jens T. Siveke, Roland M. Schmid, Clara Lubeseder-Martellato
Ana Hidalgo-Sastre, Judit Desztics, Zahra Dantes, Katharina Schulte, Hilal Kabadayi Ensarioglu, Blessing Bassey-Archibong, Rupert Öllinger, Thomas Engleiter, Lyndsay Rayner, Henrik Einwächter, Juliet M. Daniel, Ali Sameer Abdulghani Altaee, Katia Steiger, Marina Lesina, Roland Rad, Maximilian Reichert, Guido von Figura, Jens T. Siveke, Roland M. Schmid, Clara Lubeseder-Martellato
View: Text | PDF
Research Article Oncology

Loss of Wasl improves pancreatic cancer outcome

  • Text
  • PDF
Abstract

Several studies have suggested an oncogenic role for the neural Wiskott-Aldrich syndrome protein (N-WASP, encoded by the Wasl gene), but thus far, little is known about its function in pancreatic ductal adenocarcinoma (PDAC). In this study, we performed in silico analysis of WASL expression in PDAC patients and found a correlation between low WASL expression and prolonged survival. To clarify the role of Wasl in pancreatic carcinogenesis, we used 2 oncogenic Kras–based PDAC mouse models with pancreas-specific Wasl deletion. In line with human data, both mouse models had an increased survival benefit due to either impaired tumor development in the presence of the tumor suppressor Trp53 or the delayed tumor progression and senescent phenotype upon genetic ablation of Trp53. Mechanistically, loss of Wasl resulted in cell-autonomous senescence through displacement of the N-WASP binding partners WASP-interacting protein (WIP) and p120ctn; vesicular accumulation of GSK3β, as well as YAP1 and phosphorylated β-catenin, which are components of the destruction complex; and upregulation of Cdkn1a(p21), a master regulator of senescence. Our findings, thus, indicate that Wasl functions in an oncogenic manner in PDAC by promoting the deregulation of the p120-catenin/β-catenin/p21 pathway. Therefore, strategies to reduce N-WASP activity might improve the survival outcomes of PDAC patients.

Authors

Ana Hidalgo-Sastre, Judit Desztics, Zahra Dantes, Katharina Schulte, Hilal Kabadayi Ensarioglu, Blessing Bassey-Archibong, Rupert Öllinger, Thomas Engleiter, Lyndsay Rayner, Henrik Einwächter, Juliet M. Daniel, Ali Sameer Abdulghani Altaee, Katia Steiger, Marina Lesina, Roland Rad, Maximilian Reichert, Guido von Figura, Jens T. Siveke, Roland M. Schmid, Clara Lubeseder-Martellato

×

Figure 6

Combined salinomycin and LMB treatment of CKP-NΔPanc tumor cells rescues the senescent phenotype.

Options: View larger image (or click on image) Download as PowerPoint
Combined salinomycin and LMB treatment of CKP-NΔPanc tumor cells rescues...
(A) CKP-NΔPanc cells were treated with Cytochalasin D (2 μM), salinomycin (1 μM), or EIPA (25 μM) for 48 hours; then, the cells were fixed and stained for GSK3β. Scale bars: 10 μM. (B) CKP-NΔPanc cells were treated as described for A, harvested, and analyzed by Western blot. (C) Three CKP-NΔPanc cell lines were treated as described for A for 24 hours and harvested, and the relative Cdkn1a(p21) expression was analyzed by RT-PCR. Student′s t test. (D) CKP-NΔPanc cells were grown on a thin layer of collagen and treated with salinomycin; then, the cells fixed stained for SA–β-galactosidase and quantified. The mean of 2 cell lines ± SEM is shown. Student′s t test. (E) CKP-NΔPanc cells were treated with LMB (5 ng/mL) for 20 hours; then, the cells were fixed and stained for p120ctn. Scale bars: 50 μM. (F) CKP-NΔPanc cells were grown on a thin layer of collagen and sequentially treated with 1M salinomycin and 5 ng/mL LMB; then, the cells fixed stained for SA–β-galactosidase. A representative image is shown. Scale bars: 50 μM. (G) Quantification of the treatment described in F; each treatment was performed in triplicates. The mean of 3 cell lines ± SEM is shown. Student′s t test. (H) Cell lines were treated as described for panel F. The relative Cdkn1a(p21) expression of 2 cell lines is shown. Student′s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts